S15:02 Dapirolizumab pegol and flare reduction in patients with SLE in a 48-week phase 3 trial: an updated post hoc analysis of alternative definitions of flares that reflect clinical practice

Richard Furie, C. Stach, L. M. Carter et al.|Oral Presentations|2026

Cited by 0